Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus au… Read more
Basilea Pharmaceutica AG (BPMUF) - Net Assets
Latest net assets as of June 2025: $103.16 Million USD
Based on the latest financial reports, Basilea Pharmaceutica AG (BPMUF) has net assets worth $103.16 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($248.85 Million) and total liabilities ($145.69 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $103.16 Million |
| % of Total Assets | 41.45% |
| Annual Growth Rate | -10.74% |
| 5-Year Change | N/A |
| 10-Year Change | 439.99% |
| Growth Volatility | 128.19 |
Basilea Pharmaceutica AG - Net Assets Trend (2012–2024)
This chart illustrates how Basilea Pharmaceutica AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Basilea Pharmaceutica AG (2012–2024)
The table below shows the annual net assets of Basilea Pharmaceutica AG from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $81.00 Million | +909.83% |
| 2023-12-31 | $-10.00 Million | +77.78% |
| 2022-12-31 | $-45.01 Million | +23.20% |
| 2021-12-31 | $-58.61 Million | +42.57% |
| 2020-12-31 | $-102.05 Million | -9.77% |
| 2019-12-31 | $-92.96 Million | -39.40% |
| 2018-12-31 | $-66.69 Million | -60.92% |
| 2017-12-31 | $-41.44 Million | -18.40% |
| 2016-12-31 | $-35.00 Million | -333.33% |
| 2015-12-31 | $15.00 Million | -92.33% |
| 2014-12-31 | $195.69 Million | -18.28% |
| 2013-12-31 | $239.45 Million | -24.40% |
| 2012-12-31 | $316.73 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Basilea Pharmaceutica AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17929945600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $13.17 Million | 16.26% |
| Other Comprehensive Income | $-4.74 Million | -5.86% |
| Other Components | $995.87 Million | 1229.48% |
| Total Equity | $81.00 Million | 100.00% |
Basilea Pharmaceutica AG Competitors by Market Cap
The table below lists competitors of Basilea Pharmaceutica AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Instalco Intressenter AB
ST:INSTAL
|
$662.14 Million |
|
Sansiri Public Company Limited
BK:SIRI-R
|
$662.14 Million |
|
Hunan Keli Motor Co Ltd
SHE:002892
|
$662.42 Million |
|
Hongrun Construction Group Co Ltd
SHE:002062
|
$662.62 Million |
|
HBL Power Systems Limited
NSE:HBLPOWER
|
$661.89 Million |
|
Gambol Pet Group Co Ltd Class A
SHE:301498
|
$661.70 Million |
|
NORBIT ASA NK-1
F:4NK
|
$661.62 Million |
|
Hornbach Holding AG & Co. KGaA
LSE:0RC9
|
$661.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Basilea Pharmaceutica AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -10,002,000 to 80,999,000, a change of 91,001,000.
- Net income of 77,593,000 contributed positively to equity growth.
- New share issuances of 2,439,000 increased equity.
- Other comprehensive income increased equity by 5,468,000.
- Other factors increased equity by 5,501,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $77.59 Million | +95.8% |
| Share Issuances | $2.44 Million | +3.01% |
| Other Comprehensive Income | $5.47 Million | +6.75% |
| Other Changes | $5.50 Million | +6.79% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Basilea Pharmaceutica AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.24x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-76.61 | $54.00 | x |
| 2013-12-31 | $7.30 | $54.00 | x |
| 2014-12-31 | $5.82 | $54.00 | x |
| 2015-12-31 | $1.48 | $54.00 | x |
| 2016-12-31 | $-3.46 | $54.00 | x |
| 2017-12-31 | $-3.82 | $54.00 | x |
| 2018-12-31 | $-6.15 | $54.00 | x |
| 2019-12-31 | $-8.64 | $54.00 | x |
| 2020-12-31 | $-9.93 | $54.00 | x |
| 2021-12-31 | $-5.02 | $54.00 | x |
| 2022-12-31 | $-3.77 | $54.00 | x |
| 2023-12-31 | $-0.82 | $54.00 | x |
| 2024-12-31 | $5.85 | $54.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Basilea Pharmaceutica AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 95.80%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 37.21%
- • Asset Turnover: 0.81x
- • Equity Multiplier: 3.18x
- Recent ROE (95.80%) is above the historical average (-33.32%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -91.63% | 0.15x | 0.00x | $20.41 Million |
| 2013 | -46.59% | -80.63% | 0.14x | 4.23x | $-40.11 Million |
| 2014 | -71.72% | -97.76% | 0.17x | 4.44x | $-47.34 Million |
| 2015 | -410.69% | -119.26% | 0.13x | 26.60x | $-63.10 Million |
| 2016 | 0.00% | -77.73% | 0.20x | 0.00x | $-47.79 Million |
| 2017 | 0.00% | -19.07% | 0.29x | 0.00x | $-15.22 Million |
| 2018 | 0.00% | -23.65% | 0.47x | 0.00x | $-24.68 Million |
| 2019 | 0.00% | -16.69% | 0.61x | 0.00x | $-13.13 Million |
| 2020 | 0.00% | -11.53% | 0.56x | 0.00x | $-4.52 Million |
| 2021 | 0.00% | -4.61% | 0.60x | 0.00x | $-970.30K |
| 2022 | 0.00% | 8.22% | 0.67x | 0.00x | $16.65 Million |
| 2023 | 0.00% | 6.63% | 0.91x | 0.00x | $11.45 Million |
| 2024 | 95.80% | 37.21% | 0.81x | 3.18x | $69.49 Million |
Industry Comparison
This section compares Basilea Pharmaceutica AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Basilea Pharmaceutica AG (BPMUF) | $103.16 Million | 0.00% | 1.41x | $661.96 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |